Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listingNigel S B. RawsonJohn Adams
关键词: CANADA PHARMACEUTICAL policy TREATMENT of rare diseases ORPHAN drugs MEDICAL care MEDICAL care costs HEALTH services accessibility GOVERNMENT policy HEALTH services accessibility laws ORPHAN drug laws SYMPTOMS ECONOMICS DOI: 10.1503/cmaj.170195 年份: 2017 ...
Orphan Drugs Market Analysis The Global Orphan Drugs Market size is estimated at USD 230.91 billion in 2025, and is expected to reach USD 312.53 billion by 2030, at a CAGR of 6.24% during the forecast period (2025-2030). The COVID-19 outbreak is an unprecedented public health concern that...
Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement [8]. Rosenberg-Yunger et al. conducted qualitative case studies to determine how drug advisory committees made reimbursement decisions for two orphan drugs in Canada, ...
The study performed a budget impact analysis using data from multiple sources to estimate the reimbursement budget for high-priced OMPs in Chengdu, a densely populated metropolis in China. The budget analysis consisted of three main elements: the number of patients, the price of drugs, and the ...
Canada Rarediseases 2025 To Collaborate Scientific Professionals around the World Conference Date October 27-28, 2025 For Sponsors & Exhibitors sponsor@conferenceseries.com Speaker Opportunity Poster Opportunity E-Poster Opportunity Useful Links Past Conference Report Rarediseases 2024 Conference Supported...
A Editorial - 《Drugs in R & D》 被引量: 0发表: 2005年 Summary Basis of Decision (SBD): Diacomit - 2013 - Health Canada Health Canada Summary Basis of Decision 2013-02-21. Diacomit, Stiripentol, 250 mg, 500 mg, DIN: 02398958, 02398966, 02398974, 02398982, Biocodex SA, New Dr.....
Canada ORPHAN DRUGS 2024 About Conference Why to Attend? Sessions & Tracks Abstract Submission Guidelines: Market Analysis: About Conference The Orphan DrugsConferences Committee is pleased to announce the"4th World Congress on Rare Diseases & Orphan Drugs,"which will be held inParis, FrancefromSeptem...
Canada: Special access program (SAP) The SAP provides access to non-marketed drugs and medical devices for physicians treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. ...
Join the 14th World Congress on Rare Diseases and Orphan Drugs, June 2-3, 2025, in Amsterdam. Explore breakthroughs in research, treatment, and innovation to transform rare disease care globally.